Comprehensive Geriatric Assessment and Management for Canadian Elders With Cancer

Clinical and Cost-effectiveness of a Comprehensive Geriatric Assessment and Management for Canadian Elders With Cancer: the 5C Study

A multicentre two-group parallel single-blind (outcome assessor) randomized controlled trial (RCT). A cost effectiveness study alongside a clinical trial using a payer and societal perspective to study the cost-effectiveness of geriatric assessment and management compared to usual care will be conducted.

Participants allocated to the control group will receive usual oncology care. Participants allocated to the intervention group will receive a comprehensive geriatric assessment and management in addition to their usual oncology care. The intervention will take 6 months to be completed. Total study follow-up will be 12 months for each participant.

Inclusion Criteria:

• Patients aged 70+ with any solid tumor (excluding pancreatic) or lymphoma/myeloma referred for first/second line adjuvant/curative or palliative chemotherapy (cannot have received more than 1 cycle),
• Able to speak English/French,
• Have a physician-estimated life expectancy >6 months,
• Have an ECOG Performance Score 0-2 (indicating participants are ambulatory and able to complete all self-care activities),
• Able to give informed consent.

Exclusion Criteria:

• Receiving palliative care services upon recruitment
• Already participating in another psychosocial/educational intervention study (new treatment study is allowed if the participants would like to participate in 2 studies)